The role of magnetoplasmons in Casimir force calculations

In this paper we review the role of magneto plasmon polaritons in the Casimir force calculations. By applying an external constant magnetic field a strong optical anisotropy is induced on two parallel slabs reducing the reflectivity and thus the Casimir force. As the external magnetic field increases, the Casimir force decreases. Thus, with an an external magnetic field the Casimir force can be controlled.The calculations are done in the Voigt configuration where the magnetic field is parallel to the slabs. In this configuration the reflection coefficients for TE and TM modes do not show mode conversion.Comment: contribution to QFEXT09, Norman, Oklahoma 200

Pull-in control due to Casimir forces using external magnetic fields

We present a theoretical calculation of the pull-in control in capacitive micro switches actuated by Casimir forces, using external magnetic fields. The external magnetic fields induces an optical anisotropy due to the excitation of magneto plasmons, that reduces the Casimir force. The calculations are performed in the Voigt configuration, and the results show that as the magnetic field increases the system becomes more stable. The detachment length for a cantilever is also calculated for a cantilever, showing that it increases with increasing magnetic field. At the pull-in separation, the stiffness of the system decreases with increasing magnetic field.Comment: accepted for publication in App. Phys. Let

Transverse magnetic surface plasmons and complete absorption supported by doped graphene in Otto configuration

High sensitivity of the Attenuated Total Reflectance technique for exciting transverse magnetic surface plasmons in free-standing doped graphene is reported; complete agreement with the electromagnetic dispersion relation is numerically demonstrated in the terahertz regime. By reducing the air gap between prism and graphene in the Otto configuration we found that the surface plasmon excitation is weakened, but interference effects arise producing perfect absorption. At 5 THz two dips of zero-reflection were found, one of them with residual plasmonic contribution. Consequently, the reflection can be suppressed by changing the separation between prism and graphene; it is not needed to modify the graphene doping level. Conditions for destructive interference leading to complete absorption are presented and a particular behavior of the evanescent magnetic fields just at perfect absorption is reporte

Hartman effect in one-dimensional photonic crystals with a three-level atomic defect layer

The Hartman effect in one-dimensional photonic crystals contained a defect layer doped with two-level, and three-level atoms is discussed. It is shown that the transmitted phase time in one-dimensional photonic crystals contained a defect layer reaches to a positive constant as the periodic number N increases. However, for a defect layer doped by two-level atoms, the transmitted phase time reaches to negative constant by increasing periodic number N. In addition, for defect layer doped by three-level atoms, the transmitted phase time can be controlled from positive to negative just by the Rabi-frequency of coupling field

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)